Hypersensitivity and Loss of Disease Site Targeting Caused by Antibody Responses to PEGylated Liposomes
Open Access
- 1 February 2006
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy
- Vol. 13 (2), 328-337
- https://doi.org/10.1016/j.ymthe.2005.09.014
Abstract
The systemic application of nucleic acid drugs requires delivery systems that overcome the poor pharmacokinetics, limited biodistribution, and inefficient uptake of nucleic acids. PEGylated liposomes show considerable promise because of their intrinsic ability to accumulate at disease sites and facilitate transfection of target cells. Unlike many viral vectors, PEGylated liposomes are generally considered to be nonimmunogenic. We have developed a PEGylated liposome for the systemic administration of plasmid DNA that achieves high levels of selective gene expression at distal tumor sites. Here we report that the in vivo efficacy and safety of these systems can be severely compromised following repeat administration. This phenomenon is characterized by a loss of disease site targeting, accelerated clearance from the blood, and acute hypersensitivity. These effects are fully attributable to a surprisingly robust, long-lived antibody response generated against polyethylene glycol (PEG) that results from the strong adjuvant effect of the plasmid payload. Importantly, immunogenicity may be substantially reduced by modifying the alkyl chain of the PEG–lipid conjugate, thereby allowing successful repeat dosing of the modified plasmid formulations without adverse side effects. Immunogenicity is a relevant concern for a number of nonviral delivery systems given the potent immunostimulatory properties of many nucleic acid drugs.Keywords
This publication has 45 references indexed in Scilit:
- Induction of Inflammatory Cytokines and Interferon Responses by Double-stranded and Single-stranded siRNAs is Sequence-dependent and Requires Endosomal LocalizationJournal of Molecular Biology, 2005
- Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic AcidJournal of Pharmacology and Experimental Therapeutics, 2004
- TLR9 signals after translocating from the ER to CpG DNA in the lysosomeNature Immunology, 2004
- Pharmacokinetics of Pegylated Liposomal DoxorubicinClinical Pharmacokinetics, 2003
- Interleukin 15 Controls both Proliferation and Survival of a Subset of Memory-Phenotype CD8+ T CellsThe Journal of Experimental Medicine, 2002
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- Tc-99m-PEG-Liposomes for the Evaluation of Colitis in Crohn's DiseaseJournal of Drug Targeting, 2000
- Accelerated Clearance of Polyethylene Glycol-Modified Proteins by Anti-Polyethylene Glycol IgMBioconjugate Chemistry, 1999
- Thymus-independent antigens: complexity of B-lymphocyte activation revealedImmunology Today, 1982
- Biological stability of [3H]cholesteryl oleyl ether in cultured fibroblasts and intact ratFEBS Letters, 1980